The National Institute for Health and Clinical Excellence (NICE) are in the process of reviewing Rimonabant for the treatment of overweight and obese adults.
The Appraisal Committee are due to meet again early next year to produce a Final Appraisal Determination but the preliminary recommendations indicate that NICE is unlikely to recommend rimonabant. They have requested additional information from the manufacturer to include evidence from the clinical trials on health outcomes (including cardiovascular risk factors) and evidence on the cost effectiveness of rimonabant compared with diet and exercise alone, as well as the cost effectiveness of rimonabant compared with orlistat and sibutramine.
Action: Clinicians should avoid starting new patients on rimonabant until full guidance is published. Patients who are currently on treatment can continue treatment, within licensed indications, while it continues to be effective.
Thanks to NPCi for the original article
|« December CKS Update||December NICE Guidance »|